Literature DB >> 30505705

Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma.

Marius Ilie1,2,3, Paul Hofman1,2,3.   

Abstract

Entities:  

Year:  2018        PMID: 30505705      PMCID: PMC6249616          DOI: 10.21037/tlcr.2018.08.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  9 in total

1.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Authors:  Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

3.  Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

Authors:  Conor E Steuer; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2018-01-16       Impact factor: 44.544

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 5.  Genomic Approaches to Understanding Response and Resistance to Immunotherapy.

Authors:  David A Braun; Kelly P Burke; Eliezer M Van Allen
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

Review 6.  Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Authors:  Matthew M Gubin; Maxim N Artyomov; Elaine R Mardis; Robert D Schreiber
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Authors:  Yulian Khagi; Aaron M Goodman; Gregory A Daniels; Sandip P Patel; Assuntina G Sacco; James M Randall; Lyudmila A Bazhenova; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-10-01       Impact factor: 12.531

9.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

  9 in total
  1 in total

1.  Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?

Authors:  Pascale Tomasini; Laurent Greillier
Journal:  Transl Lung Cancer Res       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.